Faculty Profiles - TOYOOKA Shinichi

Papers - TOYOOKA Shinichi

Division display 841 - 860 of about 940 ／ All the affair displays >>

The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Reviewed

Toyooka S, Matsuo K, Shigematsu H, Kosaka T, Tokumo M, Yatabe Y, Ichihara S, Inukai M, Suehisa H, Soh J, Kiura K, Fong KM, Lee H, Wistuba II, Gazdar AF, Mitsudomi T, Date H

Clinical cancer research : an official journal of the American Association for Cancer Research 13 ( 19 ) 5763 - 5768 2007.10

肺リンパ脈管筋腫症による生体肺移植後の難治性胸腹水に対するSirolimusの投与経験

大原利章, 佐野由文, 三好健太郎, 田尾裕之, 山根正修, 豊岡伸一, 大藤剛宏, 岡崎恵, 伊達洋至

移植 42 ( 総会臨時 ) 240 - 240 2007.10

EGFR変異とUFTによる肺腺癌術後補助療法の関連性についての検討

末久弘, 豊岡伸一, 堀田勝幸, 内田亜希子, 宗淳一, 藤原義朗, 松尾恵太郎, 大内田守, 高田穣, 木浦勝行, 伊達洋至

肺癌 47 ( 5 ) 513 - 513 2007.10

肺非小細胞癌における治療前血清KL-6値とゲフィチニブ単剤療法の治療効果の関連

藤原義朗, 木浦勝行, 瀧川奈義夫, 豊岡伸一, 堀田勝幸, 宗淳一, 田端雅弘, 加藤勝也, 伊達洋至, 谷本光音

肺癌 47 ( 5 ) 629 - 629 2007.10

抗悪性腫瘍薬の至適投与法確立を目指して非小細胞肺癌(NSCLC)症例における、腫瘍EGFR遺伝子変異の殺細胞性抗癌剤治療効果への影響の検討

堀田勝幸, 木浦勝行, 豊岡伸一, 瀧川奈義夫, 宗淳一, 藤原義朗, 田端雅弘, 伊達洋至, 谷本光音

肺癌 47 ( 5 ) 450 - 450 2007.10

ゲフィチニブにて治療したNSCLC患者の血清KL-6値の予後的意義(Prognostic value of serum KL-6 level in NSCLC patients treated with gefitinib)

藤原義朗, 木浦勝行, 瀧川奈義夫, 豊岡伸一, 堀田勝幸, 宗淳一, 田端雅弘, 加藤勝也, 伊達洋至, 谷本光音

日本癌治療学会誌 42 ( 2 ) 370 - 370 2007.9

Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20 mm or less. Reviewed

Kobayashi N, Toyooka S, Soh J, Ichimura K, Yanai H, Suehisa H, Ichihara S, Yamane M, Aoe M, Sano Y, Date H

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2 ( 9 ) 808 - 812 2007.9

Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. Reviewed

Suehisa H, Toyooka S, Hotta K, Uchida A, Soh J, Fujiwara Y, Matsuo K, Ouchida M, Takata M, Kiura K, Date H

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25 ( 25 ) 3952 - 3957 2007.9

早期肺癌に対する治療戦略末梢小型肺癌に対するラジオ波焼灼術(RFA)の有用性の検討

佐野由文, 平木隆夫, 郷原英夫, 三村秀文, 金澤右, 山根正修, 豊岡伸一, 大藤剛宏, 伊達洋至

日本癌治療学会誌 42 ( 2 ) 262 - 262 2007.9

日本人の悪性胸膜中皮腫におけるP16遺伝子のホモ欠失とp16発現の不活化(Homozygous deletions of Pffigene and inactivation of p16 expression in Japanese malignant pleural mesothelioma)

小林成行, 豊岡伸一, 市原周治, 宗淳一, 市村浩一, 柳井広之, 藤本伸一, 岸本卓巳, 末久弘, 伊達洋至

日本癌学会総会記事 66回 130 - 130 2007.8

Living-donor lobar lung transplantation for pulmonary arterial hypertension after failure of epoprostenol therapy. Reviewed

Date H, Kusano KF, Matsubara H, Ogawa A, Fujio H, Miyaji K, Okazaki M, Yamane M, Toyooka S, Aoe M, Sano Y, Hanazaki M, Goto K, Kasahara S, Sano S, Ohe T

Journal of the American College of Cardiology 50 ( 6 ) 523 - 527 2007.8

扁桃腫瘤で発見された再発肺腺癌

武田洋正, 瀧川奈義夫, 木浦勝行, 大橋圭明, 大澤昌宏, 田端雅弘, 谷本光音, 豊岡伸一, 伊達洋至

肺癌 47 ( 4 ) 387 - 387 2007.8

Long-term improvement in pulmonary function after living donor lobar lung transplantation. Reviewed

Yamane M, Date H, Okazaki M, Toyooka S, Aoe M, Sano Y

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 26 ( 7 ) 687 - 692 2007.7

EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib. Reviewed

Soh J, Toyooka S, Ichihara S, Suehisa H, Kobayashi N, Ito S, Yamane M, Aoe M, Sano Y, Kiura K, Date H

Lung cancer (Amsterdam, Netherlands) 56 ( 3 ) 445 - 448 2007.6

Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion. Reviewed

Katayama H, Hiraki A, Aoe K, Fujiwara K, Matsuo K, Maeda T, Murakami T, Toyooka S, Sugi K, Ueoka H, Tanimoto M

International journal of cancer. Journal international du cancer 120 ( 10 ) 2191 - 2195 2007.5

The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants. Reviewed

Toyooka S, Uchida A, Shigematsu H, Soh J, Ogino A, Takata M, Kiura K, Ouchida M, Kosaka T, Aoe M, Mitsudomi T, Date H

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2 ( 4 ) 321 - 324 2007.4

EGFR変異とUFTによる肺腺癌術後補助療法の関連性についての検討

末久弘, 豊岡伸一, 堀田勝幸, 内田亜希子, 宗淳一, 木浦勝行, 浅野博昭, 藤原義朗, 松尾恵太郎, 青江基, 高田穣, 清水信義, 伊達洋至

日本呼吸器外科学会雑誌 21 ( 3 ) 404 - 404 2007.4

Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers Reviewed

Kunitoshi Tomii, Kazunori Tsukuda, Shinichi Toyooka, Hideaki Dote, Tadashi Hanafusa, Hiroaki Asano, Minoru Naitou, Hiroyoshi Doihara, Takumi Kisimoto, Hideki Katayama, Harvery I. Pass, Hiroshi Date, Nobuyoshi Shimizu

INTERNATIONAL JOURNAL OF CANCER 120 ( 3 ) 566 - 573 2007.2

Language：English Publishing type：Research paper (scientific journal) Publisher：WILEY-LISS

Insulin-like growth factor binding protein-3 (IGFBP-3) is postulated to be a mediator of growth suppression signals. Here, we examined the methylation status of IGFBP-3 to correlate to clinicopathological factors in human cancers. The methylation status of IGFBP-3 was determined by bisulfite DNA sequencing and was correlated with expression semi-quantified by real-time RT-PCR to develop a methylation-specific PCR (MSP) assay for IGFBP-3. Using the MSP assay, we examined the methylation status of IGFBP-3 in gastric cancer (GC), colorectal cancer (CRC), breast cancer (BC) and malignant mesothelioma (MM). IGFBP-3 methylation was detected in 6 of 13 (46%) and 16 of 24 (67%) GC cell lines and tumors, respectively; 4 of 8 (50%) and 15 of 26 (58%) CRC cell lines and tumors, respectively; 3 of 11 (27%) and 7 of 39 (18%) BC cell lines and tumors, respectively and 1 of 5 (20%) and 18 of 56 (32%) MM cell lines and tumors, respectively. Interestingly, the methylation status of MM specimens from Japanese patients (75%, 12 out of 16 patients) was significantly higher than those from the USA (15%, 6 out of 40 patients) (p < 0.0001), suggesting the presence of ethnic differences in the IGFBP-3 methylation status. We also found that IGFBP-3 methylation was preferentially present in GCs arising in the lower-third of the stomach (p = 0.079). In summary, our results showed that IGFBP-3 methylation played an important role in the silencing of its expression, suggesting that IGFBP-3 may act as a tumor suppressor gene in several human cancers examined. (c) 2006 Wiley-Liss, Inc.

DOI： 10.1002/ijc.22341

Web of Science

researchmap

PS-032-3 肺癌におけるEGFR遺伝子変異のタイプとその臨床病理学的特徴(基礎研究6, 第24回日本呼吸器外科学会総会号)

重松久之, 鈴木実, 豊岡伸一, 木村秀樹, 藤澤武彦, 伊達洋至

日本呼吸器外科学会雑誌 21 ( 3 ) 404 - 404 2007

Cytomegalovirus infection in lung transplantation; current status, detection, prophylactic treatment

Motoi Aoe, H. Tao, M. Yamane, S. Toyooka, Y. Sano, M. Okazaki, H. Date

Kyobu geka. The Japanese journal of thoracic surgery 60 ( 11 ) 988 - 992 2007

Language：Japanese Publishing type：Research paper (scientific journal)

The control of the postoperative infectious disease is one of the important elements in transplantation. Among them, the control of the cytomegalovirus (CMV) infection may be said the most important in the management of the transplant recipient who is under the immunosuppression. This time, we review the status of the pre-transplant CMV infection in the donors and recipients of both brain-death and living-related lung transplantation that we performed, and report our prophylactic treatment for CMV infection and its results. The CMV positive rate of the recipients and donors of the lung transplantation that we experienced in Okayama University was 87%. We experienced 4 cases that developed CMV infection after lung transplantation. However, there is no case that died of a CMV-related infectious disease after lung transplantation to date. By the CMV mismatch transplant, it seemed that the frequency of the postoperative CMV disease was high in comparison with the transplant of recipient CMV (+). But, the control of the CMV infection after lung transplantation is thought to be possible if we give a proper prophylactic treatment even in CMV mismatch transplantation.

Scopus

PubMed

researchmap

　 PREV - NEXT 　

< TOYOOKA Shinichi >

Papers - TOYOOKA Shinichi